Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease

Acta Neurologica Scandinavica

Volumn 98, Issue 2, 1998, Pages 142-144

  Muller T ^a   Blum Degen, D ^b   Przuntek, H ^a   Kuhn, W ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cytokines; Interleukin 6; Parkinson's disease; Severity of disease

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; PARKINSON DISEASE;

EID: 0031857454     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb01736.x     Document Type: Article

References (12)

1. MCGEER PL, MCGEER EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995: 21: 195-218.
2. KUHN W, MÜLLER T. Neuroimmune mechanisms in Parkinson's disease. J Neural Transm Suppl 1995: 46: 217-28.
3. HAMA T, KUSHIMA Y, MIYAMOTO M, KUBOTA M, TAKEI N, HATANAKA H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 1991: 40: 445-52.
4. LEE SC, LIU W, DICKSON DW, BROSNAN CF, BERMAN JW. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 1993: 150: 2659-67.
5. WOODROOFE MN. Cytokine production in the central nervous system. Neurology 1995: 45: 6-10.
6. KALMAN J, JUHASZ A, LAIRD G et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol Scand 1997: 96: 236-40.
7. MOGI M, HARADA M, KONDO T et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994: 180: 147-50.
8. 123I]-Iodolisuride SPET visualizes dopaminergic loss in "denovo" Parkinsonian patients: Is it a marker of striatal presynaptic degeneration? Nucl Med Commun 1997: 18: 1115-21.
9. MARSDEN CD. Parkinson's Disease. J Neurol Neurosurg Psychiatry 1994: 57: 672-81.
10. LEE CS, SCHULZER M, MAK E, HAMMERSTAD JP, CALNE S, CALNE DB. Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis. Neurology 1995: 45: 435-9.
11. KUHN W, MÜLLER TH, KRÜGER R, PRZUNTEK H. Selegiline stimulates biosynthesis of cytokines interleukin-1 beta and interleukin-6. Neuroreport 1996: 7: 2847-48.
12. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993: 328: 176-83.